Tryton Medical has announced the completion of enrolment in the Extended Access Registry, a single arm study of its Tryton side branch stent. The Tryton registry is designed to confirm the results from Tryton’s pivotal Investigational Device Exemption (IDE) trial, and has successfully enrolled 133 patients from Europe and the USA.
Nitinol Devices & Components (NDC) has successfully completed the acquisition of Interface Catheter Solutions. The two companies will create Confluent Medical Technologies.
Abbott Vascular has announced that it has entered into an agreement to purchase Tendyne Holdings, which is a private medical device company focused on developing minimally invasive mitral valve replacement therapies. It has also provided capital and secured an option to purchase Cephea Valve Technologies—a private company that is developing a catheter-based mitral valve replacement therapy. Financial terms were not disclosed.
Bellerophon Therapeutics has announced top-line results from its PRESERVATION I clinical trial for Bioabsorbable Cardiac Matrix (BCM), an investigational, implantable medical device being studied for the prevention of heart failure following an acute myocardial infarction.
Augusto D Pichard, interventional cardiologist at Washington Hospital Center and professor of medicine at the George Washington University Medical Center, will discuss how robotic-assisted percutaneous coronary interventions (PCI) are applied in a modern cath lab during his presentation entitled “Robotic Coronary Angioplasty” at the 24th Annual Meeting of the Japanese Association of Cardiovascular Intervention and Therapeutics: CVIT 2015 (July 30–1 August, Fukuoka City, Japan).
The 7 Tesla (T) scanner Magnetom Terra is the first fully designed and manufactured by Siemens, with a new 7T magnet in its core, and comes with the lightest actively shielded 7T whole body magnet in the world, according to a company press release.
To meet both clinical and research needs of magnetic resonance imaging (MRI) customers, Toshiba America Medical Systems has implemented software and hardware upgrades for the Vantage TitanTM 3T MRI system. Available both for new Titan 3T MRI systems and for existing installations, Toshiba says that the upgrades improve image quality and workflow “so those in both the clinical and research settings have access to the highest levels of performance and information to provide the best possible care.”
The PRAGUE 13 (Multivessel coronary disease diagnosed at the time of PPCI for STEMI: complete revascularization versus conservative strategy) trial indicates that treating culprit and non-culprit stenoses, through staged percutaneous coronary intervention (PCI), is not associated with significantly better outcomes than only treating the culprit vessel in patients with ST-segment elevation myocardial infarction (STEMI) and multivessel disease. These results are different from those of previous studies that have indicated that complete revascularisation does confer a benefit.
The US Food and Drug Administration (FDA) has granted conditional approval for a US investigational device exemption clinical trial to examine the use of Thoratec’s HeartMate PHP acute catheter-based heart pump in patients undergoing a high-risk percutaneous coronary intervention.
Maquet Getinge Group has announced the publication of a manuscript describing the exploration of the haemodynamic effects of the newer, larger-capacity 50 cc intra-aortic balloon pumps (IABPs) versus 40 cc IABPs in real-world clinical practice. The paper, “Hemodynamic effects of standard versus larger-capacity intra-aortic balloon counter-pulsation pumps,” appears in The Journal of Invasive Cardiology.
InspireMD’s CGuard embolic prevention system has posted positive results in the PARADIGM study, led by principal investigator Piotr Musialek, as reported at the EuroPCR 2015 meeting (19–22 May, Paris, France).
For years, the radiology industry has focused on reducing, or eliminating patient exposure to radiation. Recently, the industry has shifted attention to the cumulative effect radiation exposure has over the course of a physician’s career.
Albert Starr has received the 2015 Institut de France’s Grand Prix Scientifique, which is one of the largest prizes for scientific accomplishment and is considered the world’s most prestigious prize for cardiovascular research. In 1960, Starr performed the world’s first successful artificial mitral valve implant in Oregon, USA, on a 52-year-old man with end-stage mitral valve disease. That same year, Miles Lowell Edwards incorporated Edwards Laboratories to manufacture and market the Starr-Edwards valve.
JenaValve Technology has announced the appointment of seasoned medical device executive Victoria E. Carr-Brendel as chief executive officer, effective immediately.
Merit Medical Systems has launched the Prelude Snap splittable sheath introducer. The Prelude snap’s design is based directly on physician feedback.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos